These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
543 related articles for article (PubMed ID: 29175158)
21. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity. Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768 [TBL] [Abstract][Full Text] [Related]
22. Updates to the antitumor mechanism of oncolytic virus. Bai Y; Hui P; Du X; Su X Thorac Cancer; 2019 May; 10(5):1031-1035. PubMed ID: 30900824 [TBL] [Abstract][Full Text] [Related]
23. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis. Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245 [TBL] [Abstract][Full Text] [Related]
24. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment. Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741 [TBL] [Abstract][Full Text] [Related]
31. Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy. Bishnoi S; Tiwari R; Gupta S; Byrareddy SN; Nayak D Viruses; 2018 Feb; 10(2):. PubMed ID: 29473868 [TBL] [Abstract][Full Text] [Related]
32. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas. Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y Front Immunol; 2021; 12():721830. PubMed ID: 34675919 [TBL] [Abstract][Full Text] [Related]
33. Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. Zhu Z; McGray AJR; Jiang W; Lu B; Kalinski P; Guo ZS Mol Cancer; 2022 Oct; 21(1):196. PubMed ID: 36221123 [TBL] [Abstract][Full Text] [Related]
34. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models. Patel MR; Dash A; Jacobson BA; Ji Y; Baumann D; Ismail K; Kratzke RA Cancer Gene Ther; 2019 Nov; 26(11-12):411-418. PubMed ID: 30622322 [TBL] [Abstract][Full Text] [Related]
35. Oncolytic Viruses: Therapeutics With an Identity Crisis. Breitbach CJ; Lichty BD; Bell JC EBioMedicine; 2016 Jul; 9():31-36. PubMed ID: 27407036 [TBL] [Abstract][Full Text] [Related]
36. Arming oncolytic viruses to leverage antitumor immunity. de Gruijl TD; Janssen AB; van Beusechem VW Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450 [TBL] [Abstract][Full Text] [Related]
37. Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model. Dobson CC; Naing T; Beug ST; Faye MD; Chabot J; St-Jean M; Walker DE; LaCasse EC; Stojdl DF; Korneluk RG; Holcik M Oncotarget; 2017 Jan; 8(2):3495-3508. PubMed ID: 27966453 [TBL] [Abstract][Full Text] [Related]
38. Synergistic interaction between oncolytic viruses augments tumor killing. Le Boeuf F; Diallo JS; McCart JA; Thorne S; Falls T; Stanford M; Kanji F; Auer R; Brown CW; Lichty BD; Parato K; Atkins H; Kirn D; Bell JC Mol Ther; 2010 May; 18(5):888-95. PubMed ID: 20234341 [TBL] [Abstract][Full Text] [Related]